You are here

  • Home
  • Archive
  • Volume 5, Issue 6
  • Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea

Article Text

Article menu

Download PDFPDF

XML
Diabetes and endocrinology
Research
Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea
  1. Sang Ouk Chin1,
  2. Choon Hee Chung2,
  3. Yoon-Sok Chung3,
  4. Byung-Joon Kim4,
  5. Hee Young Kim5,
  6. In-Ju Kim6,
  7. Jung Guk Kim7,
  8. Min-Seon Kim8,
  9. Seong-Yeon Kim9,
  10. Eun Jig Lee10,
  11. Ki Young Lee4,
  12. Sung-Woon Kim11
  1. 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea
  2. 2Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Korea
  3. 3Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea
  4. 4Department of Endocrinology and Metabolism, Gachon University Gil Medical Center, Incheon, Korea
  5. 5Division of Endocrinology and Metabolism, Department of Endocrinology, Korea University College of Medicine, Seoul, Korea
  6. 6Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea
  7. 7Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyungpook University School of Medicine, Daegu, Korea
  8. 8Department of Internal Medicine, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea
  9. 9Department of Internal Medicine, Seoul National University School of Medicine, Seoul, Korea
  10. 10Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
  11. 11Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea
  1. Correspondence to Professor Sung-Woon Kim; igf1{at}unitel.co.kr

Abstract

Objectives This study was designed to investigate changes in health-related quality of life (HRQoL) of patients with acromegaly in Korea after medical treatment with octreotide LAR using the validated Korean version of the acromegaly quality of life questionnaire (AcroQoL).

Design A prospective, open-label, single-arm study.

Setting 11 tertiary centres in Korea.

Participants 58 Korean patients (aged 21–72 years) who were newly diagnosed with acromegaly between 2009 and 2012 were prescribed octreotide LAR 20 mg at the time of enrolment. During 24 weeks of observation, AcroQoL survey questionnaires and measurement of growth hormone insulin-like growth factor 1(GH/IGF-I) were performed at baseline, week 12 and week 24.

Main outcome measures We assessed the HRQoL of Korean patients with acromegaly after medical treatment with octreotide LAR using the validated Korean version of the AcroQoL questionnaire.

Results Patients had a mean age of 47.2 years (29 males), and GH and IGF-I significantly decreased during the first 12 weeks (GH: 4.8 vs 1.9 μg/L, p<0.001; IGF-I: 497 vs 265 μg/L, p<0.001), but showed insignificant change at week 24 (GH: 2.3 μg/L; IGF-I: 294 μg/L). Only AcroQoL scores for the psychological appearance subdomain showed a significant increase during the entire 24 weeks (p<0.05). The change in the psychological appearance subdomain of AcroQoL scores demonstrated a significant but weak negative correlation with change in IGF-I levels (r=−0.282, p=0.039). When patients were divided into two groups according to their disease activity at week 24 (controlled vs uncontrolled), there was no difference in AcroQoL scores, but the psychological appearance subdomain of the two groups appeared to change differently over the entire 24-week period (p=0.047).

Conclusions: Medical treatment with octreotide LAR in patients with acromegaly has a limited contribution to HRQoL as assessed by the AcroQoL.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/bmjopen-2014-006898

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text